[go: up one dir, main page]

WO2018105929A1 - Composition pour prévenir ou traiter une déficience cognitive comprenant un extrait de feuilles d'atemoya ou une fraction de celui-ci - Google Patents

Composition pour prévenir ou traiter une déficience cognitive comprenant un extrait de feuilles d'atemoya ou une fraction de celui-ci Download PDF

Info

Publication number
WO2018105929A1
WO2018105929A1 PCT/KR2017/013247 KR2017013247W WO2018105929A1 WO 2018105929 A1 WO2018105929 A1 WO 2018105929A1 KR 2017013247 W KR2017013247 W KR 2017013247W WO 2018105929 A1 WO2018105929 A1 WO 2018105929A1
Authority
WO
WIPO (PCT)
Prior art keywords
leaf extract
fraction
disease
extract
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/013247
Other languages
English (en)
Korean (ko)
Inventor
정수진
임혜선
김유진
김부여
서창섭
이미영
손은진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2018105929A1 publication Critical patent/WO2018105929A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material

Definitions

  • the present invention relates to a composition for the prevention or treatment of cognitive dysfunction comprising an extract of Atenoya leaf (Annona atemoya leaf), specifically, for the prevention or treatment of cognitive dysfunction comprising the atetoya leaf extract or fractions thereof
  • Cognitive impairment which loses the ability of cognitive function, can be divided into dementia and mild cognitive impairment.
  • Mild cognitive dysfunction complains of subjective memory impairment or abnormalities found in objective tests, but it does not interfere with daily life and mental function is maintained so that it is not dementia.
  • Mild cognitive dysfunction is more common than dementia, and 15 to 30% of 60-year-olds may fall within this category and increase with age.
  • the condition of mild cognitive dysfunction is the current cognitive impairment between normal and Alzheimer's disease, and about 15% annually develops symptoms of dementia. Dementia is expected to surpass 100 million people with dementia, 3.1 times larger than 2013, by 2050. Korea is expected to become the fastest growing country for dementia in the world due to the aging population of over 65%. As a significant social concern.
  • Dementia not a specific disease name, refers to a specific state of cognitive decline, and there are about 100 kinds of causative diseases.
  • Alzheimer's disease which is a degenerative brain disease, accounts for over 50% of dementia, and the exact cause and treatment of symptoms such as irreversible behavior, personality changes, and decreased thinking ability caused by Alzheimer's disease are not known.
  • amyloid-beta protein accumulation and oxidative stress due to the impaired function of the cholinergic nervous system, the neurotransmitter system, and inflammatory reactions have been reported (Lancet, 21, 1403, 1976; J. Biol. Chem., 273). , 29719, 1988; Science, 262, 689, 1993), has been found to be closely associated with impaired cognitive function.
  • Athemoya is a tropical fruit of the Anonaaceae, a hybrid of the American family of annona squamosa and annona cherimola, with a variety of varieties such as Hillary White and Pinks Marmose. Its shape resembles the head of a Buddha, and in China and Taiwan, it has no sour taste and is said to have the highest sugar content among fruits, and is grown in Jeju in Korea. Athemoya's immature fruits are dysentery, tumors, rashes, etc., petals are watery, antispasmodic, and the ethanol extract of seeds is used for folk remedies as insecticides and insect repellents, and roots are used for diarrhea and fever. And has been reported to inhibit tumors.
  • the antithrombotic effect of atemoya seed ethanol extract can be used as an anticancer drug (BMC Complement Altern Med. 2014 Sep 23; 14: 353), and antibacterial, antioxidant and Anti-inflammatory activity has been reported (Food Chem. 2016 Jul 1; 202: 176-83) and the treatment or prevention of degenerative encephalopathy with tryptamine, the active ingredient of atemeya seed extract, has been reported ( U.S. Patent No. 8614246), the effect on the cognitive dysfunction of the atmoya leaf extract has not been found.
  • the present inventors have made efforts to find natural products that have a low side effect and are harmless to the human body while exhibiting the effect of preventing, improving or treating cognitive dysfunction.
  • the excellent amyloid beta aggregation inhibitory, antioxidant effect, and cell of Atemeya leaf extract or fractions thereof The present invention was completed by confirming that there is a nontoxic and neuronal cell protective effect, and confirming that it can be applied to drugs or foods.
  • Another object of the present invention is to provide a method for preventing or treating cognitive dysfunction comprising administering the composition to a subject.
  • Still another object of the present invention is to provide a health functional food composition for preventing or improving cognitive dysfunction, including an extract of Annona atemoya leaf or a fraction thereof.
  • Still another object of the present invention is to provide a feed composition for preventing or improving cognitive dysfunction, including an Atenaya leaf (Annona atemoya leaf) extract or a fraction thereof.
  • composition comprising the atemonia leaf extract or fractions thereof of the present invention inhibits amyloid beta aggregation, and has a high antioxidant effect, nontoxic to neurons and protects the neurons from external stimuli, thereby preventing cognitive dysfunction, It can be applied to medicine or health food for treatment or improvement.
  • Figure 1 shows the manufacturing process of the fraction according to an embodiment of the present invention.
  • Figure 2 is a graph showing the effect of the leaves of Athemoya leaves, seeds and pulp extract on amyloid beta aggregation (Morin; positive control group, the same below).
  • Figure 3 is a graph showing the antioxidant efficacy of the leaves, seeds and pulp extract through DPPH radical scavenging ability (Vit. C; positive control group, the same below).
  • Figure 4 is a graph showing the antioxidant efficacy of the leaves, seeds and pulp extract through DPPH radical scavenging ability.
  • FIG. 5 is a graph showing cytotoxicity of atemonia leaf, seed and pulp extract against neuronal hippocampal cell line ( ** P ⁇ 0.01).
  • Figure 6 is a graph showing the protective effect of the Athemoya leaves, seeds and pulp extract using HT22 cells (Carvedilol: positive control, ### P ⁇ 0.001 vs. extract untreated, ** P ⁇ 0.01, *** P ⁇ 0.001 vs. H 2 O 2 single treatment group)
  • FIG. 7 is a graph showing the effect of atemonia leaf extract fractions on amyloid beta aggregation.
  • Figure 8 is a graph showing the antioxidant efficacy of the Athemoya leaf extract fraction through ABTS radical scavenging ability.
  • Figure 9 is a graph showing the antioxidant efficacy of the Atemeia leaf extract fractions through DPPH radical scavenging ability.
  • Figure 10 is a graph showing the effect on the improvement of cognitive dysfunction of Atehya leaf extract through behavioral experiment in Alzheimer's dementia animal model (Morin; positive control group, ### P ⁇ 0.001 vs. normal group, * P ⁇ 0.05, *** P ⁇ 0.001 vs. Amyloid beta group).
  • FIG. 11 is a graph showing the effects of atorectile dysfunction of the Athemoya leaf extract through a behavioral experiment in a short-term memory loss animal model (Tacrine; positive control group, # P ⁇ 0.05, ### P ⁇ 0.001 vs. normal group) , * P ⁇ 0.05, ** P ⁇ 0.01 vs. Scopolamine administered group).
  • One aspect of the present invention for achieving the above object provides a pharmaceutical composition for preventing or treating cognitive dysfunction, including an extract (Anona atemoya leaf) or fractions thereof.
  • the present invention also provides a prophylactic or therapeutic use of atemoya leaf extract or fractions thereof.
  • Annona atemoya is a tropical fruit of the Anpoaceae family, which is a hybrid of the sugar apple (annona squamosa) and annona cherimola native to the US tropical region.
  • the leaves were compared to the leaves, seeds and pulp extract, the remarkably excellent effect of the leaves of the leaves and cognitive dysfunction was first identified by the present inventors.
  • the athemoya leaves, seeds and pulp of the present invention can be purchased and used commercially.
  • extract refers to an extract obtained by extracting the atamoya leaves, a diluent or concentrate of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, a mixture thereof, and the like. , Extracts themselves and extracts of all formulations that can be formed using the extracts.
  • the extract or fraction of the present invention may be prepared and used in the form of a dry powder after extraction.
  • the method of extracting the atamoya leaf is not particularly limited, and may be extracted according to a method commonly used in the art.
  • Non-limiting examples of the extraction solvent may include water, alcohol or a mixed solvent thereof, and, when using alcohol as a solvent, it is possible to use C1 to C4 alcohol as an example.
  • the atemonia leaf extract of the present invention may be an ethanol extract.
  • the extract may be concentrated or removed by performing a filtration process under reduced pressure, or further concentrated and / or lyophilized after performing the extraction or fractionation process, the obtained atemaya leaf extract is used until Can be stored in a quick freezer.
  • fraction refers to the result obtained by performing fractionation to separate a specific component or a specific group of components from a mixture comprising various various components.
  • the fractionation method for obtaining the fraction is not particularly limited, and may be performed according to a method commonly used in the art.
  • the fractionation method there is a method of obtaining a fraction from the extract by treating the extract obtained by extracting the leaves of Athemoya with a predetermined solvent.
  • the kind of the fractionation solvent used to obtain the fraction in the present invention is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the fractionation solvents include polar solvents such as water and alcohols; Non-polar solvents such as hexane, ethyl acetate, chloroform, dichloromethane and the like. These may be used alone or in combination of two or more thereof.
  • Alcohols of C1 to C4 may be preferably used.
  • the fractions of the atmoeya leaf extract of the present invention may be specifically hexane, ethyl acetate, saturated butanol and water fractions.
  • the term "cognitive function” refers to various intellectual abilities such as attention, perception, memory, language, and executive ability.
  • the cognitive dysfunction may mean a degenerative brain disease selected from the group consisting of forgetfulness, Alzheimer's disease, dementia, Parkinson's disease, Peak disease, and Huntington's disease.
  • Dementia is a syndrome in which the cognitive function of various areas such as memory, language, and judgment are reduced, and thus cannot perform daily life properly, and the brain function is damaged by various causes. As a result, the overall decline may result in significant disruption in daily life.
  • the dementia can be divided into dozens of causative diseases, but among them, Alzheimer's disease is the most common cause and exceeds 50%.
  • dementia can be caused by degenerative brain diseases such as Lewy dementia, frontal lobe degeneration, Parkinson's disease, and various causes such as normal pressure hydrocephalus, head trauma, brain tumors, metabolic diseases, deficiency diseases, addictive diseases, and infectious diseases. have.
  • amyloid beta aggregation inhibitory activity is significantly superior to the Athemoya seed and pulp extract of the Athemoya leaf extract of the present invention (Fig. 2); ABTS and DPPH radical scavenging ability was confirmed to have a high antioxidant activity (Fig. 3 and 4).
  • the Atemonia leaf extract showed no toxicity to neurons (FIG. 5); It was confirmed that the survival rate of neurons was improved by using HT22 cells induced neuronal damage (FIG. 6).
  • behavioral tests such as passive avoidance experiments and Y-maze experiments using mice induced with Alzheimer's dementia and short-term memory loss confirmed the effects of improving the cognitive function of the Athemoya leaf extract (FIGS. 10 and 11). ).
  • Atmoeya leaf extract can be very useful for preventing, treating or improving cognitive dysfunction.
  • the ethyl acetate fractions compared to the hexane, saturated butanol and water fractions were found to have significantly superior amyloid beta aggregation inhibitory activity (Fig. 7); High antioxidant activity was confirmed through ABTS and DPPH radical scavenging activity (FIGS. 8 and 9). This suggests that the fraction of the atamoya leaf extract, specifically, the ethyl acetate fraction can be very usefully used for the prevention, treatment or improvement of cognitive dysfunction.
  • prevention refers to any action that inhibits or delays cognitive dysfunction by administration of a pharmaceutical composition comprising the atemonia leaf extract of the present invention or a fraction thereof.
  • treatment refers to any behavior in which cognitive dysfunction is improved or beneficially altered by administration of the pharmaceutical composition.
  • the pharmaceutical composition of the present invention may include 0.01% to 100% by weight of the atemonia leaf extract or fractions thereof, based on the total weight of the composition, specifically, 1% to 80% by weight, but is not limited thereto.
  • the pharmaceutical composition for preventing or treating a cognitive function-related disease according to the present invention may further include a pharmaceutically acceptable carrier, and may be formulated together with the carrier to be provided as a food, medicine, feed additive, and drinking water additive. Can be.
  • the term “pharmaceutically acceptable carrier” may refer to a carrier or diluent that does not interfere with the biological activity and properties of the compound to be injected without stimulating the organism.
  • the kind of the carrier usable in the present invention is not particularly limited, and any carrier can be used as long as it is a conventionally used and pharmaceutically acceptable carrier in the art.
  • Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more.
  • the composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations.
  • the carrier may include a non-naturally occuring carrier.
  • it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used.
  • the carrier, excipient and diluent may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, Polyvinyl pyrrolidone, saline, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol and liquid paraffin, but Without limitation, conventional carriers, excipients or diluents can be used.
  • the ingredients may be added independently or in combination with the active ingredient atemeya leaf extract.
  • Solid form preparations for oral administration may include tablet pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or It can be prepared by mixing lactose, gelatin and the like.
  • excipients such as starch, calcium carbonate, sucrose or It can be prepared by mixing lactose, gelatin and the like.
  • lubricants such as magnesium stearate, talc and the like can also be used.
  • Liquid preparations for oral administration include suspensions, solution solutions, emulsions, and syrups, and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have.
  • Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the pharmaceutical composition of the present invention is a group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories It can have any one formulation selected from.
  • the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount.
  • the pharmaceutical compositions of the present invention may be prepared in consideration of the effective amount range, and the unit dosage form formulated in this way may be formulated using a specialized dosage method according to the judgment of a professional who monitors or observes the administration of the drug as required and the needs of the individual. It can be used or administered several times at regular time intervals.
  • the pharmaceutical composition of the present invention may be administered at 0.0001 to 1000 mg / kg per day, more specifically at 0.01 to 100 mg / kg, based on the amount of atemonia leaf extract. It may be administered once or divided several times.
  • a method for treating cognitive dysfunction comprising administering to the subject a pharmaceutical composition comprising the atemonia leaf extract or a fraction thereof as an active ingredient.
  • the atmoya, extracts, fractions, cognitive dysfunction, prevention and treatment are as described above.
  • the term "administration" refers to the introduction of a predetermined substance to a subject in an appropriate manner and the route of administration of the composition can be administered via any general route as long as it can reach the desired tissue.
  • the term "individual” means any animal, including humans, who may or may have a cognitive dysfunction. As a specific example, it may be a mammal including a human.
  • Another aspect of the invention provides a dietary supplement for the prevention or improvement of cognitive dysfunction, including the Athemoya leaf extract.
  • the atmoya, extracts, fractions, cognitive function, prevention and treatment are as described above.
  • the term " improvement" means any action that at least reduces the parameters associated with the condition, e.g., the degree of symptoms, treated with the administration of a composition comprising the atemonia leaf extract of the present invention or a fraction thereof.
  • the atamoya leaf extract or a fraction thereof may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method.
  • the mixed amount of the active ingredient can be suitably determined according to the purpose of use (prevention, health or therapeutic treatment), and the composition of the present invention is environmentally friendly and there is no problem in terms of stability, so there is no big limitation in the mixing amount.
  • the health functional food composition of the present invention can be expected to be ingested on a daily basis, the effect of improving cognitive dysfunction can be expected, and thus can be very useful for health promotion purposes.
  • the term "health functional food” of the present invention is the same term as a food for special health use (FOSHU), and foods having high medical effects and medical effects processed to efficiently exhibit bioregulatory functions in addition to nutritional supply. Means.
  • the term 'function' refers to obtaining a useful effect for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body.
  • the health functional food of the present invention can be prepared by a method commonly used in the art, and the preparation can be prepared by adding raw materials and ingredients commonly added in the art.
  • the formulation of the health functional food can also be prepared without limitation as long as the formulation is recognized as a food.
  • the health functional food composition of the present invention can be prepared in various forms of formulations, unlike the general medicine has the advantage that there is no side effect that can occur when taking long-term use of the drug as a raw material, and excellent portability
  • the health functional food of the present invention can be ingested as an adjuvant for enhancing the cognitive dysfunction effect.
  • the health functional food means a food having an active health maintenance or promotion effect compared to the general food
  • health supplement food means a food for health supplement purposes.
  • nutraceutical, health food, dietary supplement are used interchangeably.
  • the health functional food is a food prepared by adding the compound of the present invention to food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, etc.
  • food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, etc.
  • the health functional food composition may further include a physiologically acceptable carrier, and the type of carrier is not particularly limited and may be used as long as it is commonly used in the art.
  • the health functional food composition may include additional ingredients that are commonly used in food compositions to improve the smell, taste, time and the like.
  • additional ingredients may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like.
  • minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn) and copper (Cu); And amino acids such as lysine, tryptophan, cysteine, valine and the like.
  • the health functional food composition is a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetic acid, etc.), fungicides (bleaching powder and highly bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisol (BHA), Butylhydroxytoluene (BHT), etc.), colorant (such as tar pigment), coloring agent (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasoning (such as MSG glutamate), sweetener (ducin, cyclate , Saccharin, sodium, etc.), fragrances (vanillin, lactones, etc.), swelling agents (alum, D-potassium hydrogen titanate, etc.), reinforcing agents, emulsifiers, thickeners (pigments), coatings, gum herbicides, foam inhibitors, solvents, modifiers, etc. May contain food additives.
  • the additive may be selected according to the type
  • An example of the health functional food composition of the present invention can be used as a health beverage composition, in which case it may contain various flavors or natural carbohydrates as additional ingredients, such as conventional drinks.
  • the above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin, cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol.
  • Sweeteners include natural sweeteners such as taumartin, stevia extract; Synthetic sweeteners such as saccharin and aspartame;
  • the ratio of the natural carbohydrate may be generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 mL of the health beverage composition of the present invention.
  • the health beverage composition includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, Alcohol or carbonation agent and the like.
  • Others may contain fruit flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components can be used independently or in combination.
  • the ratio of such additives is not critical, but is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.
  • the present invention also provides a feed composition for the prevention or improvement of cognitive dysfunction, including the Athemoya leaf extract or a fraction thereof.
  • the content of atomeya leaf extract in the feed composition for preventing or improving cognitive dysfunction may be appropriately selected depending on the species, age, weight, and breeding conditions of the feed animals, and 0.01 to 95% by weight relative to the total weight of the feed composition, specifically As may be the ratio of 0.1 to 80% by weight.
  • the feed composition may include a feed additive.
  • the feed additive of the present invention corresponds to a feed supplement in the Feed Control Act.
  • feed may refer to any natural or artificial diet, one meal, or the like or a component of the one meal for the animal to eat, ingest, and digest.
  • the kind of the feed is not particularly limited, and may be used a feed commonly used in the art.
  • Non-limiting examples of the feed may include plant feeds such as cereals, fruits, food processing by-products, algae, fibres, pharmaceutical by-products, oils, starches, gourds or grain by-products; And animal feeds such as proteins, minerals, fats and oils, minerals, fats and oils, single cell proteins, zooplankton or foods. These may be used alone or in combination of two or more thereof.
  • the feed additive may additionally contain a carrier that is acceptable to the unit animal.
  • the feed additive may be added as it is, or a known carrier, stabilizer, or the like. If necessary, various nutrients such as vitamins, amino acids, minerals, antioxidants, and other additives may be added. Powders, granules, pellets, suspensions and the like may be in a suitable state.
  • the unit animal may be supplied alone or mixed with feed.
  • Example 1-1 Measurement of amyloid beta aggregation inhibitory efficacy
  • Amyloid beta aggregation inhibition was measured using a fluorescence assay (Thioflavin T assay).
  • Amyloid beta (A ⁇ 1 -42 ) peptide was stored at minus 80 °C, the final concentration used for the measurement was 100 ⁇ g / mL.
  • 2 mM thioflavin T as a fluorophore was used as a buffer solution for assays (assay buffer) (50 mM Tris / 150 mM NaCl (pH 7.2), 20 mM HEPES / 150 mM NaCl (pH 7.2), 10). prepared by dissolving in mM phosphate / 150 mM NaCl (pH 8.0).
  • Samples were used to prepare a final concentration of 100 ⁇ g / mL of each of the leaves, seeds and pulp extract of Preparation Example 1 in the assay buffer.
  • a ⁇ 1 -42 in order to measure the degree of agglutination inhibition 96 well plates (black microplate) thio flavin T 10 ⁇ L with A ⁇ aggregation was put 1-42 in 85 ⁇ L, and mixed with 5 ⁇ L sample made with a certain concentration fluorescence spectroscopy Measured by an analyzer.
  • the wavelength value of the fluorescence spectrometer used at this time was 440 nm / 484 nm (excitation / emission), and it measured in total for 2 hours at 37 degreeC in 20 minute intervals. Morin was used as a positive control for activity comparison.
  • the amyloid beta aggregation inhibitory activity of the athemoya leaf extract at a concentration of 100 ⁇ g / mL of the sample showed a significant activity of 69.7% of the positive control activity in the leaf extract, and 25 to At 100 ⁇ g / mL, the concentration-dependent tendency of amyloid beta aggregation inhibitory activity increased with increasing concentration.
  • the IC 50 for the inhibition of beta aggregation of the atmoeya leaf extract was 87.19 ⁇ g / mL.
  • the extract of Athemoya showed a result of increasing amyloid beta aggregation rather, and it was confirmed that the atomeya pulp extract had no effect on amyloid beta aggregation.
  • Athemoya leaf extract has superior amyloid beta aggregation inhibitory effect compared to the seed and pulp extract, and can be effective in preventing cognitive dysfunction.
  • Example 1-2-1 ABTS Radical Scavenging power Measure
  • Antioxidant activity using ABTS (3-ethyl-benzothiazoline-6-sulfonic acid) radical was measured by ABTS + ⁇ cation decolorization analysis. 7 mM ABTS and 2.45 mM potassium persulfate were uniformly mixed and left for 24 hours in the dark at room temperature to form ABTS cations (ABTS +). It was then diluted with PBS to have an absorbance value of 0.7 at 743 nm. After mixing 100 ⁇ l of each sample of Preparation Example 1 with ABTS + solution in a 96 well plate and reacting at room temperature for 30 minutes, the absorbance was measured at 743 nm using an Epoch microplate spectrophotometer. The radical scavenging activity of each sample was expressed as a percentage of the radical scavenging ability with respect to the control group using PBS as a control group. Vitamin C was used as a positive control for comparison of activity.
  • Example 1-2-2 DPPH Radical Scavenging power Measure
  • Antioxidant activity evaluation using DPPH (1-1-diphenyl-2-picrylhydrazyl) radical was carried out using a 96 well plate. 0.15 mM DPPH solution and the sample of Preparation Example 1 were uniformly mixed in the same amount in a 96 well plate and reacted at room temperature for 30 minutes, and then absorbance was measured at 517 nm. The antioxidant activity of each site extract was expressed as a percentage of radical scavenging ability with respect to the control group using the solvent DMSO as a control. Vitamin C was used as a positive control for the activity comparison.
  • the Athemoya leaf extract showed a more pronounced DPPH radical scavenging activity than the seeds and the flesh extract, and the concentration of the Athemoya leaf extract showed a concentration-dependent tendency to increase the DPPH radical scavenging activity.
  • HT22 cells were cultured in a 37% 5% CO 2 incubator using DMEM medium added with 10% FBS.
  • Cell Counting Kit-8 (CCK-8) was used according to the manufacturer's instructions. Samples were treated by concentration in HT22 cell lines (5 ⁇ 10 3 cells / well) dispensed in 96 well plates and incubated for 24 hours. After incubating for 4 hours with 10 ⁇ L of CCK-8 solution, the absorbance was measured at 450 nm and compared with each control (each extract-free (0 ⁇ g / mL) group) to determine the relative percentage of cell viability. Calculation was made (FIG. 3).
  • the atamoya leaf extract showed no cytotoxicity with almost 100% cell viability at all concentrations of 12.5 to 100 ⁇ g / mL, thus confirming the harmless safety to the human body compared to the atomeya seed and pulp extract.
  • H 2 O 2 hydrogen peroxide
  • the cell survival rate increased gradually as the concentration increased in the group treated with Atemoya leaf extract and H 2 O 2 than in the H 2 O 2 alone group compared to the control group without any treatment.
  • the survival rate of 80% similar to that of the positive control group was about 40% higher than that of the H 2 O 2 treated group.
  • the leaves extract leaves the nerve cells to protect against external stimulation, thereby improving the survival rate of the nerve cells.
  • Example 4-1 Amyloid beta aggregation inhibitory efficacy measurement
  • Amyloid beta aggregation inhibition measurement of the atmoya leaf extract fraction of Preparation Example 2 was used for fluorescence analysis (Thioflavin T assay), the specific experimental method was carried out in the same manner as in Example 1-1.
  • amyloid beta aggregation inhibitory activity of each fraction of 100 ⁇ g / mL of the sample of Atehoya leaf extract showed an excellent activity than the positive control in the ethyl acetate fraction.
  • Athemoya leaf extract fraction specifically ethyl acetate fraction has an excellent amyloid beta aggregation inhibitory effect, through which it can be effective in preventing cognitive dysfunction.
  • Antioxidant activity was measured using ABTS radicals of the Athemoya leaf extract fractions in accordance with the ABTS + cation decol orization assay using a 96-well plate, and the specific experimental method was the same as in Example 1-2-1. Was performed.
  • Antioxidant activity measurement using DPPH (1-1-diphenyl-2-picrylhydrazyl) radicals of Atemeya leaf extract fractions was performed using a 96 well plate.
  • the fractions of Atehoya leaf extract showed excellent DPPH radical scavenging activity, in particular, the ethyl DP acetate and then the excellent DPPH radical scavenging ability of the saturated butanol fraction was confirmed.
  • mice 23-28 g male mice (ICR, central laboratory animals) at 7 weeks of age had a temperature of 23 ⁇ 3 ° C, a relative humidity of 55 ⁇ 15%, a ventilation frequency of 10-20 times / hour, an illumination time of 12 hours 8 pm off) and roughness 150-300 Lux were kept in the animal room under conditions. All experimental procedures were conducted in accordance with the NIH Guidelines for the Management and Use of Laboratory Animals. Animal handling was conducted in accordance with the National Animal Welfare Law of Korea.
  • Example 5-2 Induction of Alzheimer's Dementia Animals and Athemoya Leaf extract dosage
  • Alzheimer's dementia was induced by cryopreservation for at least 3 weeks before administration to induce aggregation and administration to the third ventricle of the brain (intracerebroventricular injection, icv).
  • Atemeya leaf extract a test substance, was dissolved in PBS, and was administered orally for a total of 23 days until the end of the experiment starting the administration of amyloid beta 5 days before administration.
  • Morin an amyloid aggregation inhibitor, was used as a positive control for the test substance (FIG. 10A).
  • Example 5-3 Induction of short-term memory loss and Athemoya Leaf extract dosage
  • the test substance dissolved in PBS was administered orally for 2 weeks, and tacrine was used as a positive control group.
  • tacrine was used as a positive control group.
  • scopolamine a memory loss substance, was intraperitoneally administered 30 minutes before the behavioral experiment (FIG. 11A).
  • Passive avoidance experiments were performed at the same time for three consecutive days at 24 hour intervals.
  • the dementia-induced mice were kept in the shaded area for 2 minutes, and then placed in the illuminated area and immediately moved to the shaded area and immediately taken out for adaptive training.
  • the second day after 24 hours, two training sessions were held at two-minute intervals:
  • the mouse was placed in the passive avoidance test instrument chamber for 60 seconds to adapt to the instrument.
  • the guillotine door was opened without lighting, and the mouse was freely moved in and out. After 60 seconds of adaptation, the lamp was re-lit and allowed to freely enter and exit for 120 seconds.
  • the guillotine door was closed and 0.20 mA of scrambled shock was received for 2 seconds. The mice that did not move at this time were excluded from the experiment. On the last day, the time to move to the shaded area was measured by measuring the time as well as opening the guillotine door in the illuminated area.
  • the Y-maze is made of black acrylic in the shape of a Y-shaped blocky maze, and three branches are defined as A, B, and C, respectively, and the mouse is carefully placed on one branch and allowed to move freely for 8 minutes.
  • the branches containing the mice were recorded in order.
  • the case was entered completely to the tail, and the case was entered again to the branch which once entered.
  • One point was awarded for three different branches. Change behavior was calculated by the following equation.
  • Athemoya leaf extract may be effective in preventing cognitive dysfunction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne : une composition qui est destinée à prévenir ou à traiter une déficience cognitive, et comprend un extrait de feuilles d'Atemoya ou une fraction de celui-ci ; une méthode destinée à prévenir ou à traiter une déficience cognitive à l'aide de la composition ; et une composition alimentaire fonctionnelle de santé qui est destinée à prévenir ou à soulager une déficience cognitive, et comprend un extrait de feuilles d'Atemoya ou une fraction de celui-ci.
PCT/KR2017/013247 2016-12-07 2017-11-21 Composition pour prévenir ou traiter une déficience cognitive comprenant un extrait de feuilles d'atemoya ou une fraction de celui-ci Ceased WO2018105929A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0166158 2016-12-07
KR1020160166158A KR101874594B1 (ko) 2016-12-07 2016-12-07 아떼모야 잎 추출물 또는 이의 분획물을 포함하는 인지기능 장애의 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2018105929A1 true WO2018105929A1 (fr) 2018-06-14

Family

ID=62492072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/013247 Ceased WO2018105929A1 (fr) 2016-12-07 2017-11-21 Composition pour prévenir ou traiter une déficience cognitive comprenant un extrait de feuilles d'atemoya ou une fraction de celui-ci

Country Status (2)

Country Link
KR (1) KR101874594B1 (fr)
WO (1) WO2018105929A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001335494A (ja) * 2000-05-29 2001-12-04 Okinawa Shokuryo Kk アンジオテンシン変換酵素阻害物質
JP2012116761A (ja) * 2010-11-29 2012-06-21 Wamiles Cosmetics Kk 植物由来水蒸気蒸留含有化粧料
US8614246B2 (en) * 2009-03-02 2013-12-24 Centre National De La Recherche Scientifique (Cnrs) Indole derivatives for treating neurodegenerative diseases
KR20150064314A (ko) * 2013-12-03 2015-06-11 한국콜마주식회사 애플망고 추출물, 패션후르츠 추출물, 용과 추출물, 레드키위 추출물 및 아떼모야 추출물을 유효성분으로 함유하는 화장료 조성물
US9486441B2 (en) * 2008-04-21 2016-11-08 Signum Biosciences, Inc. Compounds, compositions and methods for making the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US861426A (en) * 1907-02-18 1907-07-30 Elisabth Believeau Hair-crimper.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001335494A (ja) * 2000-05-29 2001-12-04 Okinawa Shokuryo Kk アンジオテンシン変換酵素阻害物質
US9486441B2 (en) * 2008-04-21 2016-11-08 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
US8614246B2 (en) * 2009-03-02 2013-12-24 Centre National De La Recherche Scientifique (Cnrs) Indole derivatives for treating neurodegenerative diseases
JP2012116761A (ja) * 2010-11-29 2012-06-21 Wamiles Cosmetics Kk 植物由来水蒸気蒸留含有化粧料
KR20150064314A (ko) * 2013-12-03 2015-06-11 한국콜마주식회사 애플망고 추출물, 패션후르츠 추출물, 용과 추출물, 레드키위 추출물 및 아떼모야 추출물을 유효성분으로 함유하는 화장료 조성물

Also Published As

Publication number Publication date
KR101874594B1 (ko) 2018-07-05
KR20180066333A (ko) 2018-06-19

Similar Documents

Publication Publication Date Title
WO2016032249A1 (fr) Composition pharmaceutique contenant un extrait de vaccinium bracteatum thunb. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
KR20160088165A (ko) 양파 추출물 또는 이의 분획물을 유효성분으로 함유하는 인지기능 또는 기억능력 개선용 조성물
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2018080156A1 (fr) Composition pour la prévention, l'amélioration ou le traitement d'un trouble cognitif, contenant un extrait de potentilla fragarioides en tant que principe actif
WO2010036052A2 (fr) Composition contenant 4-o-méthylhonokiol pour traiter ou prévenir des maladies liées aux amyloïdes
WO2013105693A1 (fr) Composition pharmaceutique comprenant un extrait de cortex d'oryza sativa l. et d'hordeum vulgare var. hexastichon comme principe actif
WO2024005561A1 (fr) Composition comprenant un extrait de stewartia pseudocamellia en tant que principe actif pour la prévention ou le traitement de la démence
WO2020179982A1 (fr) Composition contenant des tiges de brocoli en tant qu'ingrédient actif pour améliorer les fonctions cognitives ou la mémoire
WO2013141581A1 (fr) Composition pharmaceutique ou aliment naturel comprenant des extraits de fruit de lonicera coerulea var. edulis en tant que principes actifs dans la prévention ou l'amélioration de maladies vasculaires cérébrales ischémiques
WO2013100340A1 (fr) Composition comprenant un extrait de dendropanax morbiferus pour améliorer la fonction sexuelle masculine
WO2018212598A1 (fr) Composition pour la prévention ou le traitement de maladies associées à une déficience cognitive, contenant un extrait d'euonymus hamiltonianus wall.
WO2016129902A1 (fr) Composition pour prévenir, soulager ou traiter le syndrome d'épuisement professionnel
WO2018080158A1 (fr) Composition pour la prévention, l'amélioration ou le traitement d'un trouble cognitif, contenant un extrait d'elaeagnus glabra en tant que principe actif
WO2014098306A1 (fr) Composition pharmaceutique pour prévenir ou traiter la démence
WO2016032250A1 (fr) Composition pharmaceutique contenant un extrait de portulaca grandiflora hook. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
WO2020138834A1 (fr) Composition pour la prévention ou le traitement de maladies de la peau comprenant de la spirée couronne de mariée
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
WO2018105929A1 (fr) Composition pour prévenir ou traiter une déficience cognitive comprenant un extrait de feuilles d'atemoya ou une fraction de celui-ci
WO2019212300A1 (fr) Composition comprenant un extrait d'aster koraiensis nakai ou une fraction de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie de parkinson
WO2018056575A1 (fr) Composition contenant un extrait du genre bauhinia pour prévenir ou traiter un dysfonctionnement cognitif
WO2018106009A1 (fr) Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires
WO2022139529A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la gastrite ou de l'ulcère gastroduodénal comprenant un extrait de cinnamomum cassia, une fraction dudit extrait, un isolat de ladite fraction ou des composés isolés à partir de ladite fraction
WO2019098568A2 (fr) Composition de soulagement, prévention ou traitement de la douleur comprenant un extrait de camellia japonica
WO2011046411A2 (fr) Extraits de marron possédant une activité de protection neurocellulaire et une activité d'inhibition de l'acétylcholinestérase, et leur utilisation
WO2018008999A1 (fr) Composition comprenant un extrait d'aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17879422

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17879422

Country of ref document: EP

Kind code of ref document: A1